Last reviewed · How we verify

NCT05742737

Frailty Index as An Indicator Associated With Postoperative Adverse Outcomes In The Older Population

Completed Last updated 10 June 2024
What this trial tests

trial testing Frailty Index in Frailty in 12,000 participants. Completed in 1 April 2023.

Timeline
1 April 2020
Primary endpoint
30 April 2022
1 April 2023

Quick facts

Lead sponsorWeidong Mi
StatusCompleted
Study typeOBSERVATIONAL
Enrollment12,000
Start date1 April 2020
Primary completion30 April 2022
Estimated completion1 April 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Weidong Mi

Who can join

65 and older, any sex, with Frailty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a observational study in China, which aims to explore the predictive effect of preoperative frailty defined by the modified frailty index in predicting postoperative survival and complications in elderly patients. The objectives of the study include: 1\. To demonstrate that the frailty scale can predict short- and long-term survival after surgery in elderly surgical patients; 2 Demonstrated that frailty as defined by this scale is associated with postoperative complications in older patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Frailty

Currently open trials in the same condition.

Other Weidong Mi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05742737.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing